학술논문

1 . Academic Journal

Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups

저자: by Greggi, Stefano; Falcone, Francesca; Aletti, Giovanni D.; Cascella, Marco; Bifulco, Francesca, et al.
소스: Journal of Gynecologic Oncology. 33(5):e60-e60

7 . Academic Journal

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

저자: by Loverix, Liselore; Vergote, Ignace; Busschaert, Pieter; Vanderstichele, Adriaan; Venken, Tom, et al.
소스: In European Journal of Cancer July 2023 188:131-139

7 . Academic Journal

Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice

저자: by Lorusso, Domenica; Colombo, Nicoletta; Herraez, Antonio Casado; Santin, Alessandro D.; Colomba, Emeline, et al.
소스: In European Journal of Cancer June 2023 186:172-184

7 . Academic Journal

Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial

저자: by Pignata, Sandro; Oza, Amit; Hall, Geoff; Pardo, Beatriz; Madry, Radoslaw, et al.
소스: In Gynecologic Oncology May 2023 172:121-129

7 . Academic Journal

Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

저자: by Monk, Bradley J; Tewari, Krishnansu S; Dubot, Coraline; Caceres, M Valeria; Hasegawa, Kosei, et al.
소스: In The Lancet Oncology April 2023 24(4):392-402

7 . Academic Journal

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

저자: by Accinno, Valentina; Altavilla, Chiara; Andreetta, Claudia; Antonelli, Giovanna; Arenare, Laura, et al.
소스: In The Lancet Oncology March 2023 24(3):286-296

7 . Academic Journal

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

저자: by O'Malley, David M.; Oza, Amit M.; Lorusso, Domenica; Aghajanian, Carol; Oaknin, Ana, et al.
소스: In Gynecologic Oncology December 2022 167(3):404-413

7 . Academic Journal

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

저자: by Mahner, Sven; Reuss, Alexander; du Bois, Andreas; Grimm, Christoph; Marth, Christian, et al.
소스: In The Lancet Oncology August 2022 23(8):e374-e384

7 . Academic Journal

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

저자: by Beretta, Giordano; Bella, Maria Angela; Bracarda, Sergio; Colombo, Nicoletta; Conteduca, Vincenza, et al.
소스: In ESMO Open June 2022 7(3)

7 . Academic Journal

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

저자: by Kristeleit, Rebecca; Lisyanskaya, Alla; Fedenko, Alexander; Dvorkin, Mikhail; de Melo, Andreia Cristina, et al.
소스: In The Lancet Oncology April 2022 23(4):465-478

공지

DAU Library